Advertisement

Immune complex reaction after successful treatment of meningococcal disease: an excellent response to IVIG.

04:44 EDT 24th May 2013 | BioPortfolio

Summary of "Immune complex reaction after successful treatment of meningococcal disease: an excellent response to IVIG."

The convalescence phase of severe meningococcal sepsis is complicated by immune complex reactions with arthritis being the commonest. No standard guidelines exist for management of such complications, but non-steroidal anti-inflammatory drugs and steroids have been used with varying success. We report excellent response to intravenous immunoglobulin in a child with immune complex reaction following meningococcal sepsis.

Affiliation

Department of Pediatric Disciplines, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Room no. 218, PO: Mawdiangdiang, Shillong, Meghalaya, 793018, India, rashnadass@rediffmail.com.

Journal Details

This article was published in the following journal.

Name: Rheumatology international
ISSN: 1437-160X
Pages:

Links

Medical and Biotech [MESH] Definitions

Disease-free Survival

Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

Immune Complex Diseases

Group of diseases mediated by the deposition of large soluble complexes of antigen and antibody with resultant damage to tissue. Besides SERUM SICKNESS and the ARTHUS REACTION, evidence supports a pathogenic role for immune complexes in many other IMMUNE SYSTEM DISEASES including GLOMERULONEPHRITIS, systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC) and POLYARTERITIS NODOSA.

Antigens

Substances that are recognized by the immune system and induce an immune reaction.

Bovine Respiratory Disease Complex

A multifactorial disease of CATTLE resulting from complex interactions between environmental factors, host factors, and pathogens. The environmental factors act as stressors adversely affecting the IMMUNE SYSTEM and other host defenses and enhancing transmission of infecting agents.

Vaccines, Dna

Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.

PubMed Articles [ 31600 Associated PubMed Articles listed on BioPortfolio]

Meningococcal disease in Asia: an under-recognized public health burden.

SUMMARYA literature search traced existing information on meningococcal disease in Asia. Reviewed data describing the epidemiology of meningococcal disease in Asia are incomplete, due in part to absen...

The burden of hospitalizations for meningococcal infection in Spain (1997-2008).

All hospital discharges and deaths related to invasive meningococcal disease, meningococcal meningitis and meningococcemia in the general population from 1997 to 2008 in Spain were obtained. Among the...

Genome Sequence of a Neisseria meningitidis Capsule Null Locus Strain from the Clonal Complex of Sequence Type 198.

Neisseria meningitidis is a commensal and accidental pathogen exclusively of humans. Although the production of polysaccharide capsules is considered to be essential for meningococcal virulence, there...

Comparison of meningococcal disease surveillance systems - United States, 2005-2008.

Meningococcal disease is a nationally notifiable disease caused by the bacterium Neisseria meningitidis. Rates of the disease have decreased since 2000 and are currently at a historic low. The Nationa...

Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease.

Meningococcal disease is an infection caused by Neisseria meningitidis. Genetic factors contribute to host susceptibility and progression to disease, but the genes responsible for disease development...

Clinical Trials [ 5020 Associated Clinical Trials listed on BioPortfolio]

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

The purpose of this study is to determine when a memory immune response after re-vaccination with Meningococcal C conjugate vaccine (Menjugate) or challenge with Meningococcal A/C polysacc...

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccina...

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Chiron Meningococcal ACWY Conjugate Vaccine administered to h...

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.

Evaluation of Meningococcal C Vaccine Programmes in Canadian Children

The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal...

Search BioPortfolio:
Advertisement
Advertisement